Co-Dx
Manufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2401 S Foothill Dr Ste D, Salt Lake City...Phone Number
(801) 438-1036Website
www.co-dx.comRevenue
<$5 MillionStock Symbol
CODXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Co-Dx
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2Read more
Co-Dx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Co-Dx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Co-Dx
Click to see if Co-Dx had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Co-Dx has new funding data
Check out if Co-Dx is spiking on competitors!
Co-Dx, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Co-Dx has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Co-Dx recently announced quarterly report
Product Launch: Get notified when Co-Dx launches new products
Recommended Actions
Reach out to Masked Content who joined Co-Dx as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Co-Dx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Co-Dx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Co-Dx.
Co-Dx financials insights
Gather financial insights about Co-Dx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$750K
2017
Stock Offering
$7.1M
2023
Grant
$2.3M
2026
Stock/Share Issuance
$3M
Co-Dx Tech Stack
A closer look at the technologies used by Co-Dx
See more technologies
Most Recent Scoops
Person-Based
Product Development, Medical Research, Accessibility, Healthcare Technology
Funding
Funding
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Facilities Relocation / Expansion
Leasing, Corporate Strategy, Manufacturing Operations
Co-Dx News & Media
Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs Analytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission...Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line
Visit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer SALT LAKE CITY, June 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented...Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a...Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regions Potential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform capabilities SALT LAKE CITY, June 2, 2026 /PRNewswire/ -- Co-Diagnostics,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Co-Dx
Sign Up For FreeTo access detailed company insights
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-c... Read More
